Analyst Price Targets — CMPX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 5, 2026 9:33 pm | Maury Raycroft | Jefferies | $9.00 | $5.53 | StreetInsider | Compass Therapeutics (CMPX) PT Raised to $9 at Jefferies |
| February 13, 2026 1:13 pm | — | Craig-Hallum | $15.00 | $6.52 | TheFly | Compass Therapeutics initiated with a Buy at Craig-Hallum |
| February 4, 2026 11:36 am | — | Canaccord Genuity | $13.00 | $6.42 | TheFly | Compass Therapeutics price target raised to $13 from $10 at Canaccord |
| January 6, 2026 3:11 pm | Sean McCutcheon | Raymond James | $9.00 | $4.89 | StreetInsider | Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) |
| December 3, 2025 10:02 am | Reni Benjamin | JMP Securities | $10.00 | $5.22 | TheFly | Compass Therapeutics initiated with an Outperform at Citizens JMP |
| October 6, 2025 10:30 am | — | Compass Point | $10.00 | $3.70 | TheFly | Compass Therapeutics initiated with an Outperform at LifeSci Capital |
| April 2, 2025 10:17 am | Andrew Berens | Leerink Partners | $6.00 | $1.69 | TheFly | Compass Therapeutics upgraded to Outperform from Market Perform at Leerink |
| September 16, 2024 6:49 am | Aydin Huseynov | Compass Point | $5.00 | $1.65 | StreetInsider | Ladenburg Thalmann Upgrades Compass Therapeutics (CMPX) to Buy |
Latest News for CMPX
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company.
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected to be reported in April. Based on previously reported responses in patients with triple-negative breast cancer (TNBC)…
Purchased 2,532,419 shares in CMPX; position value was $13,599,090 as of December 31, 2025 Quarter-end value of the CMPX stake was $13,599,090, resulting from the new position initiated during the quarter Transaction represented a 1.89% change relative to the fund's reported 13F AUM Post-trade holding: 2,532,419 shares valued at $13.60 million as of December 31, 2025 The new CMPX stake represented 1.89% of AUM,…
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CMPX.
U.S. House Trading
No House trades found for CMPX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.